The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication retatrutide, taken once a week, can help prevent heart and kidney problems in adults with obesity who also have heart disease or kidney disease.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 10,000 people Planned (estimated).

Who can join Ages 45+ · all sexes

Timeline Started 2024-04 · est. completion 2029-02

Where 745 sites · Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Mexico, Netherlands, New Zealand, Poland, Puerto Rico, Romania, Slovakia, Spain, Turkey (Türkiye), Ukraine, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT06383390 ↗

Description as written by the study sponsor.

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.

Treatments tested

Retatrutide also known as LY3437943 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Time to First Occurrence of Composite Endpoints
Sponsor	Eli Lilly and Company
Conditions studied	Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
GLP-1 drugs	retatrutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06383390 ↗